What is Rapid Pathogen Screening?
Rapid Pathogen Screening, also known as RPS Diagnostics, is an emerging developer, manufacturer, and marketer of point-of-care (POC) tests designed to address systemic infectious diseases and promote antibiotic stewardship. The company's flagship product, the FebriDx test, is a disposable, in-office diagnostic tool that utilizes a finger-stick blood sample. It aims to rapidly identify a clinically significant immune response and differentiate between bacterial and viral causes of fever in acute respiratory infections. With a reported negative predictive value of 97% and results available within 15 minutes, FebriDx provides clinicians with actionable data during initial patient visits, potentially guiding decisions on antibiotic prescriptions.
How much funding has Rapid Pathogen Screening raised?
Rapid Pathogen Screening has raised a total of $34.6M across 3 funding rounds:
Unspecified
$6.3M
Debt
$28M
Debt
$350K
Unspecified (2013): $6.3M with participation from Mallitz Investment Group
Debt (2014): $28M led by OrbiMed Advisors, LLC
Debt (2020): $350K supported by PPP
Key Investors in Rapid Pathogen Screening
Mallitz Investment Group
The Mallitz Investment Group is a private investment firm focused on proprietary transactions, leveraging family capital and a network of like-minded investors. They implement institutional discipline in their investment screening and due diligence processes, aiming for risk-mitigated structures and actively managed family office platforms.
OrbiMed Advisors, LLC
OrbiMed Advisors is a specialized investment firm dedicated to the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, and diagnostics. They possess deep expertise in life sciences and healthcare business development, supporting companies at various stages of development.
PPP
Public-Private Partnership
What's next for Rapid Pathogen Screening?
The recent major strategic investment in Rapid Pathogen Screening signals a pivotal growth phase for the company. This capital infusion is likely to accelerate the commercialization and market penetration of its FebriDx test, particularly in the critical area of antibiotic stewardship. The company's focus on rapid, in-office diagnostics aligns with the growing demand for efficient healthcare solutions that can reduce unnecessary antibiotic use and improve patient outcomes. Future developments may involve expanding the test's diagnostic capabilities to other infectious diseases or enhancing its integration into existing healthcare workflows. The enterprise-level funding suggests a strategic focus on scaling operations and solidifying its market position.
See full Rapid Pathogen Screening company page
